Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

North America Bronchiectasis Market - Industry Trends and Forecast to 2028

Published by Data Bridge Market Research Private Limited Product code 991671
Published Content info 300 Pages
Delivery time: 1-2 business days
Price
Back to Top
North America Bronchiectasis Market - Industry Trends and Forecast to 2028
Published: January 1, 2021 Content info: 300 Pages
Description

North America bronchiectasis market is projected to register a CAGR of 6.1% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028.

Market Segmentation:

North America Bronchiectasis Market, By Disease Type (CF Bronchiectasis and Non-CF Bronchiectasis), Severity (Mild to Moderate and Moderate-to-Severe), Type (Diagnosis and Treatment), Drugs Type (Branded and Generics), Route of Administration (Oral, Parenteral and Inhalation), End User (Hospitals, Clinics, Home Healthcare and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country(U.S., Canada, Mexico) Industry Trends and Forecast to 2028.

Some of the major factors contributing to the growth of North America bronchiectasis market are:

  • Technological advancement for disease testing
  • Rising awareness for prevention of bronchiectasis in primary and secondary care

Market Players:

The key market players for North America bronchiectasis market are listed below:

  • Abbott
  • HERSILL
  • Home Oxygen Company
  • Inogen, Inc.
  • Boehringer Ingelheim International GmbH
  • Pfizer Inc.
  • Teva Pharmaceutical USA Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd.)
  • Medline Industries, Inc
  • Ache Laboratories Farmaceuticos S.A.
  • Horizon Therapeutics plc
  • Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.)
  • Trudell Medical International
  • GlaxoSmithKline plc.
  • AstraZeneca
  • Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Bayer AG
  • Dr. Reddy's Laboratories Ltd.
  • Sunovion Pharmaceuticals Inc. (a subsidiary of Sumitomo Dainippon Pharma Co., Ltd.)
  • Viatris Inc.
  • Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila)
  • Cipla Inc.
  • Electromed, Inc.
  • Trudell Medical International
Table of Contents

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF NORTH AMERICA BRONCHIECTASIS MARKET
  • 1.4 LIMITATIONS
  • 1.5 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 MULTIVARIATE MODELLING
  • 2.7 DISEASE TYPE LIFELINE CURVE
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.9 DBMR MARKET POSITION GRID
  • 2.10 VENDOR SHARE ANALYSIS
  • 2.11 MARKET DRUGS TYPE COVERAGE GRID
  • 2.12 SECONDARY SOURCES
  • 2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PIPELINE ANALYSIS

5 NORTH AMERICA BRONCHIECTASIS MARKET: LAWS AND REGULATIONS

6 EPIDEMIOLOGY

7 MARKET OVERVIEW

  • 7.1 DRIVERS
    • 7.1.1 RISING PATIENT POPULATION SUFFERING FROM BRONCHIECTASIS
    • 7.1.2 GROWING GERIATRIC POPULATION
    • 7.1.3 RISING NUMBER OF SMOKERS AND CONSUMPTION OF ALCOHOL
    • 7.1.4 TECHNOLOGICAL ADVANCEMENT FOR DISEASE TESTING
    • 7.1.5 GROWING DIAGNOSTIC RATE

North america Bronchiectasis Market - Industry Trends and Forecast to

  • 7.2 RESTRAINTS
    • 7.2.1 HIGH COST OF DIAGNOSTIC TOOLS
    • 7.2.2 PRODUCT RECALLS
    • 7.2.3 INAPPROPRIATE REIMBURSEMENT POLICIES
  • 7.3 OPPORTUNITIES
    • 7.3.1 RISING AWARENESS FOR PREVENTION OF BRONCHIECTASIS IN PRIMARY AND SECONDARY CARE
    • 7.3.2 INCREASING HEALTHCARE EXPENDITURE
    • 7.3.3 INCREASE IN RESEARCH REGARDING THE BRONCHIECTASIS DISEASE
    • 7.3.4 AVAILABILITY OF GENERIC DRUGS IN UNDERDEVELOPED AND DEVELOPING COUNTRIES
  • 7.4 CHALLENGES
    • 7.4.1 COMPLICATIONS IN THE TREATMENT OF BRONCHIECTASIS
    • 7.4.2 LACK OF SKILLED PROFESSIONALS
    • 7.4.3 DIAGNOSITIC CHALLENGES

8 IMPACT OF COVID-19

  • 8.1 PRICE IMPACT
  • 8.2 IMPACT ON DEMAND
  • 8.3 IMPACT ON SUPPLY CHAIN
  • 8.4 STRATEGIC DECISIONS FOR MANUFACTURERS
  • 8.5 CONCLUSION

9 NORTH AMERICA BRONCHIECTASIS MARKET, BY DISEASE TYPE

  • 9.1 OVERVIEW
  • 9.2 NON-CF BRONCHIECTASIS
  • 9.3 CF BRONCHIECTASIS

10 NORTH AMERICA BRONCHIECTASIS MARKET, BY SEVERITY

  • 10.1 OVERVIEW
  • 10.2 MILD TO MODERATE
  • 10.3 MODERATE TO SEVERE

11 NORTH AMERICA BRONCHIECTASIS MARKET, BY TYPE

  • 11.1 OVERVIEW
  • 11.2 TREATMENT
    • 11.2.1 ANTIBIOTICS
      • 11.2.1.1 MACROLIDE
        • 11.2.1.1.1 AZITHROMYCIN
        • 11.2.1.1.2 CLARITHROMYCIN
        • 11.2.1.1.3 OTHERS

North america Bronchiectasis Market - Industry Trends and Forecast to

      • 11.2.1.2 AMOXICILLIN
      • 11.2.1.3 CEPHALOSPORIN
        • 11.2.1.3.1 SECOND-GENERATION CEPHALOSPORIN
        • 11.2.1.3.2 THIRD-GENERATION CEPHALOSPORIN
      • 11.2.1.4 AMINOGLYCOSIDE
        • 11.2.1.4.1 GENTAMICIN
        • 11.2.1.4.2 TOBRAMYCIN
      • 11.2.1.5 FLUOROQUINOLONE
      • 11.2.1.6 TETRACYCLINS
      • 11.2.1.7 TRIMETHOPRIM-SULFAMETHOXAZOLE
      • 11.2.1.8 COMBINATION THERAPY
    • 11.2.2 CORTICOSTEROIDS
      • 11.2.2.1 BUDESONIDE
      • 11.2.2.2 FLUTICASONE
      • 11.2.2.3 MOMETASONE
      • 11.2.2.4 FLUNISOLIDE
      • 11.2.2.5 OTHERS
    • 11.2.3 BRONCHODILATORS
      • 11.2.3.1 LONG-ACTING BRONCHODILATORS
        • 11.2.3.1.1 FORMOTEROL
        • 11.2.3.1.2 TIOTROPIUM
        • 11.2.3.1.3 SALMETEROL
        • 11.2.3.1.4 OTHERS
      • 11.2.3.2 SHORT-ACTING BRONCHODILATORS
        • 11.2.3.2.1 ALBUTEROL
        • 11.2.3.2.2 LEVALBUTEROL
        • 11.2.3.2.3 OTHERS
    • 11.2.4 MUCUS THINNING MEDICINE
      • 11.2.4.1 CARBOCISTEINE
      • 11.2.4.2 BROMHEXINE
      • 11.2.4.3 OTHERS
    • 11.2.5 AIRWAY CLEARANCE DEVICES
      • 11.2.5.1 OSCILLATING POSITIVE EXPIRATORY PRESSURE (PEP)
      • 11.2.5.2 INTRAPULMONARY PERCUSSIVE VENTILATION (IPV)
      • 11.2.5.3 POSTURAL DRAINAGE
      • 11.2.5.4 OTHERS
    • 11.2.6 OXYGEN THERAPY
      • 11.2.6.1 OXYGEN CONCENTRATORS
      • 11.2.6.2 COMPRESSED GAS OXYGEN
      • 11.2.6.3 LIQUID OXYGEN

North america Bronchiectasis Market - Industry Trends and Forecast to

    • 11.2.7 SURGERY
      • 11.2.7.1 BRONCHOSCOPY
      • 11.2.7.2 LUNG TRANSPLANT
    • 11.2.8 OTHERS
  • 11.3 DIAGNOSIS
    • 11.3.1 CHEST CT SCAN
    • 11.3.2 SPUTUM TEST
    • 11.3.3 PULMONARY FUNCTION TEST
    • 11.3.4 X-RAY
    • 11.3.5 OTHERS

12 NORTH AMERICA BRONCHIECTASIS MARKET, BY DRUGS TYPE

  • 12.1 OVERVIEW
  • 12.2 BRANDED
  • 12.3 GENERICS

13 NORTH AMERICA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION

  • 13.1 OVERVIEW
  • 13.2 INHALATION
  • 13.3 ORAL
    • 13.3.1 TABLETS
    • 13.3.2 CAPSULES
    • 13.3.3 OTHERS
  • 13.4 PARENTERAL
    • 13.4.1 INTRAVENOUS
    • 13.4.2 SUBCUTANEOUS
    • 13.4.3 OTHERS

14 NORTH AMERICA BRONCHIECTASIS MARKET, BY END USER

  • 14.1 OVERVIEW
  • 14.2 HOSPITALS
  • 14.3 CLINICS
  • 14.4 HOME HEALTHCARE
  • 14.5 OTHERS

North america Bronchiectasis Market - Industry Trends and Forecast to

15 NORTH AMERICA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL

  • 15.1 OVERVIEW
  • 15.2 HOSPITAL PHARMACY
  • 15.3 RETAIL PHARMACY
  • 15.4 ONLINE PHARMACY
  • 15.5 OTHERS

16 NORTH AMERICA BRONCHIECTASIS MARKET BY GEOGRAPHY

  • 16.1 OVERVIEW
  • 16.2 NORTH AMERICA
    • 16.2.1 U.S.
    • 16.2.2 CANADA
    • 16.2.3 MEXICO

17 NORTH AMERICA BRONCHIECTASIS MARKET: COMPANY LANDSCAPE

  • 17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

18 SWOT

19 COMPANY PROFILES

  • 19.1 ASTRAZENECA
    • 19.1.1 COMPANY SNAPSHOT
    • 19.1.2 REVENUE ANALYSIS
    • 19.1.3 COMPANY SHARE ANALYSIS
    • 19.1.4 PRODUCT PORTFOLIO
    • 19.1.5 RECENT DEVELOPMENTS
  • 19.2 GLAXOSMITHKLINE PLC.
    • 19.2.1 COMPANY SNAPSHOT
    • 19.2.2 REVENUE ANALYSIS
    • 19.2.3 COMPANY SHARE ANALYSIS
    • 19.2.4 PRODUCT PORTFOLIO
    • 19.2.5 RECENT DEVELOPMENTS
  • 19.3 TEVA PHARMACEUTICAL USA INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
    • 19.3.1 COMPANY SNAPSHOT
    • 19.3.2 REVENUE ANALYSIS
    • 19.3.3 COMPANY SHARE ANALYSIS
    • 19.3.4 PRODUCT PORTFOLIO
    • 19.3.5 RECENT DEVELOPMENTS

North america Bronchiectasis Market - Industry Trends and Forecast to

  • 19.4 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
    • 19.4.1 COMPANY SNAPSHOT
    • 19.4.2 REVENUE ANALYSIS
    • 19.4.3 COMPANY SHARE ANALYSIS
    • 19.4.4 PRODUCT PORTFOLIO
    • 19.4.5 RECENT DEVELOPMENTS
  • 19.5 NOVARTIS AG
    • 19.5.1 COMPANY SNAPSHOT
    • 19.5.2 REVENUE ANALYSIS
    • 19.5.3 PRODUCT PORTFOLIO
    • 19.5.4 RECENT DEVELOPMENTS
  • 19.6 ABBOTT
    • 19.6.1 COMPANY SNAPSHOT
    • 19.6.2 REVENUE ANALYSIS
    • 19.6.3 PRODUCT PORTFOLIO
    • 19.6.4 RECENT DEVELOPMENT
  • 19.7 ACHE LABORATORIES FARMACEUTICOS S.A.
    • 19.7.1 COMPANY SNAPSHOT
    • 19.7.2 PRODUCT PORTFOLIO
    • 19.7.3 RECENT DEVELOPMENTS
  • 19.8 BAYER AG
    • 19.8.1 COMPANY SNAPSHOT
    • 19.8.2 REVENUE ANALYSIS
    • 19.8.3 PRODUCT PORTFOLIO
    • 19.8.4 RECENT DEVELOPMENTS
  • 19.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • 19.9.1 COMPANY SNAPSHOT
    • 19.9.2 REVENUE ANALYSIS
    • 19.9.3 PRODUCT PORTFOLIO
    • 19.9.4 RECENT DEVELOPMENT
  • 19.10 CIPLA INC.
    • 19.10.1 COMPANY SNAPSHOT
    • 19.10.2 REVENUE ANALYSIS
    • 19.10.3 PRODUCT PORTFOLIO
    • 19.10.4 RECENT DEVELOPMENTS
  • 19.11 COVIS PHARMA
    • 19.11.1 COMPANY SNAPSHOT
    • 19.11.2 PRODUCT PORTFOLIO
    • 19.11.3 RECENT DEVELOPMENT

North america Bronchiectasis Market - Industry Trends and Forecast to

  • 19.12 DR. REDDY'S LABORATORIES LTD.
    • 19.12.1 COMPANY SNAPSHOT
    • 19.12.2 REVENUE ANALYSIS
    • 19.12.3 PRODUCT PORTFOLIO
    • 19.12.4 RECENT DEVELOPMENTS
  • 19.13 ELECTROMED, INC.
    • 19.13.1 COMPANY SNAPSHOT
    • 19.13.2 REVENUE ANALYSIS
    • 19.13.3 PRODUCT PORTFOLIO
    • 19.13.4 RECENT DEVELOPMENTS
  • 19.14 HERSILL
    • 19.14.1 COMPANY SNAPSHOT
    • 19.14.2 PRODUCT PORTFOLIO
    • 19.14.3 RECENT DEVELOPMENTS
  • 19.15 HOME OXYGEN COMPANY
    • 19.15.1 COMPANY SNAPSHOT
    • 19.15.2 PRODUCT PORTFOLIO
    • 19.15.3 RECENT DEVELOPMENT
  • 19.16 HORIZON THERAPEUTICS PLC
    • 19.16.1 COMPANY SNAPSHOT
    • 19.16.2 REVENUE ANALYSIS
    • 19.16.3 PRODUCT PORTFOLIO
    • 19.16.4 RECENT DEVELOPMENT
  • 19.17 INOGEN, INC.
    • 19.17.1 COMPANY SNAPSHOT
    • 19.17.2 REVENUE ANALYSIS
    • 19.17.3 PRODUCT PORTFOLIO
    • 19.17.4 RECENT DEVELOPMENTS
  • 19.18 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
    • 19.18.1 COMPANY SNAPSHOT
    • 19.18.2 REVENUE ANALYSIS
    • 19.18.3 PRODUCT PORTFOLIO
    • 19.18.4 RECENT DEVELOPMENT
  • 19.19 MEDLINE INDUSTRIES, INC.
    • 19.19.1 COMPANY SNAPSHOT
    • 19.19.2 PRODUCT PORTFOLIO
    • 19.19.3 RECENT DEVELOPMENTS

North america Bronchiectasis Market - Industry Trends and Forecast to

  • 19.20 PFIZER INC.
    • 19.20.1 COMPANY SNAPSHOT
    • 19.20.2 REVENUE ANALYSIS
    • 19.20.3 PRODUCT PORTFOLIO
    • 19.20.4 RECENT DEVELOPMENTS
  • 19.21 SUNOVION PHARMACEUTICALS INC. (A SUBSIDIARY OF SUMITOMO DAINIPPON PHARMA CO., LTD.)
    • 19.21.1 COMPANY SNAPSHOT
    • 19.21.2 REVENUE ANALYSIS
    • 19.21.3 PRODUCT PORTFOLIO
    • 19.21.4 RECENT DEVELOPMENTS
  • 19.22 SUN PHARMACEUTICAL INDUSTRIES LTD.
    • 19.22.1 COMPANY SNAPSHOT
    • 19.22.2 REVENUE ANALYSIS
    • 19.22.3 PRODUCT PORTFOLIO
    • 19.22.4 RECENT DEVELOPMENTS
  • 19.23 TRUEDELL MEDICAL INTERNATIONAL
    • 19.23.1 COMPANY SNAPSHOT
    • 19.23.2 PRODUCT PORTFOLIO
    • 19.23.3 RECENT DEVELOPMENTS
  • 19.24 VIATRIS INC.
    • 19.24.1 COMPANY SNAPSHOT
    • 19.24.2 PRODUCT PORTFOLIO
    • 19.24.3 RECENT DEVELOPMENTS
  • 19.25 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA)
    • 19.25.1 COMPANY SNAPSHOT
    • 19.25.2 REVENUE ANALYSIS
    • 19.25.3 PRODUCT PORTFOLIO
    • 19.25.4 RECENT DEVELOPMENTS

20 QUESTIONNAIRE

21 RELATED REPORTS

LIST OF TABLES

  • TABLE 1 NORTH AMERICA BRONCHIECTASIS MARKET, PIPELINE ANALYSIS 52
  • TABLE 2 REGULATION IMPOSED BY SEVERAL REGULATORY AGENCIES IN DIFFERENT REGIONS 53
  • TABLE 3 HEALTHCARE EXPENDITURE IN ASIA-PACIFIC 69
  • TABLE 4 THE PRICE OF X-RAY MACHINE 73
  • TABLE 5 NORTH AMERICA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION) 79
  • TABLE 6 NORTH AMERICA NON-CF BRONCHIECTASIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 80
  • TABLE 7 NORTH AMERICA CF BRONCHIECTASIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 81
  • TABLE 8 NORTH AMERICA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 85
  • TABLE 9 NORTH AMERICA MILD TO MODERATE BRONCHIECTASIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 86
  • TABLE 10 NORTH AMERICA MODERATE TO SEVERE BRONCHIECTASIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 87
  • TABLE 11 NORTH AMERICA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 91
  • TABLE 12 NORTH AMERICA TREATMENT IN BRONCHIECTASIS MARKET, BY REGION, 2017-2028 (USD MILLION) 93
  • TABLE 13 NORTH AMERICA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 93
  • TABLE 14 NORTH AMERICA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 94
  • TABLE 15 NORTH AMERICA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 94
  • TABLE 16 NORTH AMERICA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 95
  • TABLE 17 NORTH AMERICA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 95
  • TABLE 18 NORTH AMERICA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 96
  • TABLE 19 NORTH AMERICA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 97
  • TABLE 20 NORTH AMERICA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 97
  • TABLE 21 NORTH AMERICA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 98
  • TABLE 22 NORTH AMERICA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 99
  • TABLE 23 NORTH AMERICA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 99
  • TABLE 24 NORTH AMERICA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 100
  • TABLE 25 NORTH AMERICA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 101
  • TABLE 26 NORTH AMERICA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 102
  • TABLE 27 NORTH AMERICA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 102
  • TABLE 28 NORTH AMERICA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION) 107
  • TABLE 29 NORTH AMERICA BRANDED IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 108
  • TABLE 30 NORTH AMERICA GENERICS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 109
  • TABLE 31 NORTH AMERICA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 113
  • TABLE 32 NORTH AMERICA INHALATION IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 114
  • TABLE 33 NORTH AMERICA ORAL IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 115
  • TABLE 34 NORTH AMERICA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 115
  • TABLE 35 NORTH AMERICA PARENTERAL IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 116
  • TABLE 36 NORTH AMERICA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 116
  • TABLE 37 NORTH AMERICA BRONCHIECTASIS MARKET, BY END USER, 2019-2028 (USD MILLION) 121
  • TABLE 38 NORTH AMERICA HOSPITALS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 122
  • TABLE 39 NORTH AMERICA CLINICS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 123
  • TABLE 40 NORTH AMERICA HOME HEALTHCARE IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 124
  • TABLE 41 NORTH AMERICA OTHERS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 124
  • TABLE 42 NORTH AMERICA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 128
  • TABLE 43 NORTH AMERICA HOSPITAL PHARMACY IN BRONCHIECTASIS MARKET, REGION, 2019-2028 (USD MILLION) 129
  • TABLE 44 NORTH AMERICA RETAIL PHARMACY IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 130
  • TABLE 45 NORTH AMERICA ONLINE PHARMACY IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 130
  • TABLE 46 NORTH AMERICA OTHERS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION) 131
  • TABLE 47 NORTH AMERICA BRONCHIECTASIS MARKET, BY REGION , 2021-2028 (USD MILLION) 137
  • TABLE 48 NORTH AMERICA BRONCHIECTASIS MARKET, BY COUNTRY, 2018-2028 (USD MILLION) 142
  • TABLE 49 NORTH AMERICA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION) 142
  • TABLE 50 NORTH AMERICA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 142
  • TABLE 51 NORTH AMERICA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 142
  • TABLE 52 NORTH AMERICA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 143
  • TABLE 53 NORTH AMERICA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 143
  • TABLE 54 NORTH AMERICA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 144
  • TABLE 55 NORTH AMERICA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 144
  • TABLE 56 NORTH AMERICA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 144
  • TABLE 57 NORTH AMERICA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 144
  • TABLE 58 NORTH AMERICA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 145
  • TABLE 59 NORTH AMERICA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 145
  • TABLE 60 NORTH AMERICA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 145
  • TABLE 61 NORTH AMERICA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 145
  • TABLE 62 NORTH AMERICA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 146
  • TABLE 63 NORTH AMERICA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 146
  • TABLE 64 NORTH AMERICA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 146
  • TABLE 65 NORTH AMERICA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 146
  • TABLE 66 NORTH AMERICA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION) 147
  • TABLE 67 NORTH AMERICA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 147
  • TABLE 68 NORTH AMERICA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 147
  • TABLE 69 NORTH AMERICA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 147
  • TABLE 70 NORTH AMERICA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION) 148
  • TABLE 71 NORTH AMERICA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 148
  • TABLE 72 U.S. BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION) 149
  • TABLE 73 U.S. BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 149
  • TABLE 74 U.S. BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 149
  • TABLE 75 U.S. TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 150
  • TABLE 76 U.S. TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 150
  • TABLE 77 U.S. TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 151
  • TABLE 78 U.S. TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 151
  • TABLE 79 U.S. TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 151
  • TABLE 80 U.S. TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 151
  • TABLE 81 U.S. TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 152
  • TABLE 82 U.S. TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 152
  • TABLE 83 U.S. TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 152
  • TABLE 84 U.S. TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 152
  • TABLE 85 U.S. TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 153
  • TABLE 86 U.S. TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 153
  • TABLE 87 U.S. TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 153
  • TABLE 88 U.S. DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 153
  • TABLE 89 U.S. BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION) 154
  • TABLE 90 U.S. BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 154
  • TABLE 91 U.S. ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 154
  • TABLE 92 U.S. PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 154
  • TABLE 93 U.S. BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION) 155
  • TABLE 94 U.S. BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 155
  • TABLE 95 CANADA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION) 156
  • TABLE 96 CANADA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 156
  • TABLE 97 CANADA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 156
  • TABLE 98 CANADA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 157
  • TABLE 99 CANADA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 157
  • TABLE 100 CANADA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 158
  • TABLE 101 CANADA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 158
  • TABLE 102 CANADA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 158
  • TABLE 103 CANADA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 158
  • TABLE 104 CANADA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 159
  • TABLE 105 CANADA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 159
  • TABLE 106 CANADA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 159
  • TABLE 107 CANADA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 159
  • TABLE 108 CANADA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 160
  • TABLE 109 CANADA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 160
  • TABLE 110 CANADA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 160
  • TABLE 111 CANADA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 160
  • TABLE 112 CANADA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION) 161
  • TABLE 113 CANADA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 161
  • TABLE 114 CANADA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 161
  • TABLE 115 CANADA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 161
  • TABLE 116 CANADA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION) 162
  • TABLE 117 CANADA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 162
  • TABLE 118 MEXICO BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION) 163
  • TABLE 119 MEXICO BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION) 163
  • TABLE 120 MEXICO BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 163
  • TABLE 121 MEXICO TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 164
  • TABLE 122 MEXICO TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 164
  • TABLE 123 MEXICO TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 165
  • TABLE 124 MEXICO TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 165
  • TABLE 125 MEXICO TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 165
  • TABLE 126 MEXICO TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 165
  • TABLE 127 MEXICO TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 166
  • TABLE 128 MEXICO TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 166
  • TABLE 129 MEXICO TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 166
  • TABLE 130 MEXICO TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 166
  • TABLE 131 MEXICO TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 167
  • TABLE 132 MEXICO TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 167
  • TABLE 133 MEXICO TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 167
  • TABLE 134 MEXICO DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION) 167
  • TABLE 135 MEXICO BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION) 168
  • TABLE 136 MEXICO BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 168
  • TABLE 137 MEXICO ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 168
  • TABLE 138 MEXICO PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 168
  • TABLE 139 MEXICO BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION) 169
  • TABLE 140 MEXICO BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 169

LIST OF FIGURES

  • FIGURE 1 NORTH AMERICA BRONCHIECTASIS MARKET: SEGMENTATION 34
  • FIGURE 2 NORTH AMERICA BRONCHIECTASIS MARKET : DATA TRIANGULATION 37
  • FIGURE 3 NORTH AMERICA BRONCHIECTASIS MARKET: DROC ANALYSIS 38
  • FIGURE 4 NORTH AMERICA BRONCHIECTASIS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS 39
  • FIGURE 5 NORTH AMERICA BRONCHIECTASIS MARKET: COMPANY RESEARCH ANALYSIS 39
  • FIGURE 6 NORTH AMERICA BRONCHIECTASIS MARKET: MULTIVARIATE MODELLING 40
  • FIGURE 7 NORTH AMERICA BRONCHIECTASIS MARKET: INTERVIEW DEMOGRAPHICS 41
  • FIGURE 8 NORTH AMERICA BRONCHIECTASIS MARKET: DBMR MARKET POSITION GRID 42
  • FIGURE 9 NORTH AMERICA BRONCHIECTASIS MARKET: VENDOR SHARE ANALYSIS 43
  • FIGURE 10 NORTH AMERICA BRONCHIECTASIS MARKET: MARKET DRUGS TYPE COVERAGE GRID 44
  • FIGURE 11 NORTH AMERICA BRONCHIECTASIS MARKET: SEGMENTATION 48
  • FIGURE 12 RISING PATIENT POPULATION SUFFERING FROM BRONCHIECTASIS IS DRIVING THE NORTH AMERICA BRONCHIECTASIS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028 49
  • FIGURE 13 NON-CF BRONCHIECTASIS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA BRONCHIECTASIS MARKET IN 2021 & 2028 49
  • FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA BRONCHIECTASIS MARKET 59
  • FIGURE 15 NUMBER OF PERSONS AGED 60 YEARS ACROSS SEVERAL REGIONS IN 2017 AND 2050 61
  • FIGURE 16 PREVALENCE OF BRONCHIECTASIS BY AGE IN KOREA POPULATION (2019) 61
  • FIGURE 17 HEALTH SPENDING BY MAJOR SOURCES OF FUNDS 67
  • FIGURE 18 NORTH AMERICA BRONCHIECTASIS MARKET: BY DISEASE TYPE, 2021 75
  • FIGURE 19 NORTH AMERICA BRONCHIECTASIS MARKET: BY DISEASE TYPE, 2019-2028 (USD MILLION) 76
  • FIGURE 20 NORTH AMERICA BRONCHIECTASIS MARKET: BY DISEASE TYPE, CAGR (2021-2028) 76
  • FIGURE 21 NORTH AMERICA BRONCHIECTASIS MARKET: BY DISEASE TYPE, LIFELINE CURVE 77
  • FIGURE 22 NORTH AMERICA BRONCHIECTASIS MARKET: BY SEVERITY, 2021 81
  • FIGURE 23 NORTH AMERICA BRONCHIECTASIS MARKET: BY SEVERITY, 2019-2028 (USD MILLION) 82
  • FIGURE 24 NORTH AMERICA BRONCHIECTASIS MARKET: BY SEVERITY, CAGR(2021-2028) 82
  • FIGURE 25 NORTH AMERICA BRONCHIECTASIS MARKET: BY SEVERITY, LIFELINE CURVE 83
  • FIGURE 26 NORTH AMERICA BRONCHIECTASIS MARKET: BY TYPE, 2021 87
  • FIGURE 27 NORTH AMERICA BRONCHIECTASIS MARKET: BY TYPE, 2019-2028 (USD MILLION) 88
  • FIGURE 28 NORTH AMERICA BRONCHIECTASIS MARKET: BY TYPE, CAGR (2021-2028) 88
  • FIGURE 29 NORTH AMERICA BRONCHIECTASIS MARKET: BY TYPE, LIFELINE CURVE 89
  • FIGURE 30 NORTH AMERICA BRONCHIECTASIS MARKET: BY DRUGS TYPE, 2021 103
  • FIGURE 31 NORTH AMERICA BRONCHIECTASIS MARKET: BY DRUGS TYPE, 2019-2028 (USD MILLION) 104
  • FIGURE 32 NORTH AMERICA BRONCHIECTASIS MARKET: BY DRUGS TYPE, CAGR (2021-2028) 104
  • FIGURE 33 NORTH AMERICA BRONCHIECTASIS MARKET: BY DRUGS TYPE, LIFELINE CURVE 105
  • FIGURE 34 NORTH AMERICA BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, 2021 109
  • FIGURE 35 NORTH AMERICA BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION) 110
  • FIGURE 36 NORTH AMERICA BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028) 110
  • FIGURE 37 NORTH AMERICA BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 111
  • FIGURE 38 NORTH AMERICA BRONCHIECTASIS MARKET: BY END USER, 2021 117
  • FIGURE 39 NORTH AMERICA BRONCHIECTASIS MARKET: BY END USER, 2019-2028 (USD MILLION) 118
  • FIGURE 40 NORTH AMERICA BRONCHIECTASIS MARKET: BY END USER, CAGR (2021-2028) 118
  • FIGURE 41 NORTH AMERICA BRONCHIECTASIS MARKET: BY END USER, LIFELINE CURVE 119
  • FIGURE 42 NORTH AMERICA BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, 2021 124
  • FIGURE 43 NORTH AMERICA BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION) 125
  • FIGURE 44 NORTH AMERICA BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028) 125
  • FIGURE 45 NORTH AMERICA BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 126
  • FIGURE 46 NORTH AMERICA BRONCHIECTASIS MARKET: SNAPSHOT (2020) 131
  • FIGURE 47 NORTH AMERICA BRONCHIECTASIS MARKET: BY COUNTRY (2020) 133
  • FIGURE 48 NORTH AMERICA BRONCHIECTASIS MARKET: BY COUNTRY (2021 & 2028) 133
  • FIGURE 49 NORTH AMERICA BRONCHIECTASIS MARKET: BY COUNTRY (2020 & 2028) 134
  • FIGURE 50 NORTH AMERICA BRONCHIECTASIS MARKET: BY DISEASE TYPE (2021-2028) 134
  • FIGURE 51 NORTH AMERICA BRONCHIECTASIS MARKET: SNAPSHOT (2020) 136
  • FIGURE 52 NORTH AMERICA BRONCHIECTASIS MARKET: BY COUNTRY (2020) 138
  • FIGURE 53 NORTH AMERICA BRONCHIECTASIS MARKET: BY COUNTRY (2021 & 2028) 138
  • FIGURE 54 NORTH AMERICA BRONCHIECTASIS MARKET: BY COUNTRY (2020 & 2028) 139
  • FIGURE 55 NORTH AMERICA BRONCHIECTASIS MARKET: BY DISEASE TYPE (2021-2028) 139
  • FIGURE 56 NORTH AMERICA BRONCHIECTASIS MARKET: COMPANY SHARE 2020 (%) 168
Back to Top